Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: Results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients

Marino Clavio, Luana Vignolo, Alessandra Albarello, Riccardo Varaldo, Ivana Pierri, Gioacchino Catania, Manuela Balocco, Gianluca Michelis, Maurizio Miglino, Annunziata Manna, Enrico Balleari, A. Michele Carella, Mario Sessarego, Maria Teresa Van Lint, Andrea Bacigalupo, Marco Gobbi

Research output: Contribution to journalArticlepeer-review

Abstract

We report the final results of a prospective multi-centre trial testing the combination of chemotherapy (fludarabine, cytosine arabinoside and idarubicin; FLAI) followed by low-dose gemtuzumab ozogamicin (GO), for induction treatment of patients with CD33+ acute myeloid leukaemia (AML). Forty-six consecutive patients were treated: the median age was 66 (range: 60-80) years; the karyotype was unfavourable in 12 patients (26%), intermediate in 33 (71%) and favourable in one (3%). Eleven major infectious complications were recorded. There was one early death. Of the 45 evaluable patients, 24 achieved a complete response (CR; 52%), 66% and 33% in good-intermediate/poor karyotype patients. Median duration of CR was 7 (3-24) months. The cumulative incidence of relapse was 37% with an actuarial 2-year survival of 54%. These results were compared with 47 patients matched for age and karyotype who received FLAI, without GO. The proportion of patients achieving CR was comparable. However, patients with de novo AML receiving GO (n = 26) had a significantly lower risk of relapse at 2 years when compared with patients not receiving GO (n = 35) (40% vs. 80%, P = 0·01) and significantly better overall 2-year survival (40% vs. 14% P = 0·02). Patients with secondary AML had comparable outcome whether or not they received GO. This GO-based induction chemotherapy has a good toxicity profile. In keeping with a recent prospective randomised trial, the addition of GO seems to prolong disease-free survival.

Original languageEnglish
Pages (from-to)186-195
Number of pages10
JournalBritish Journal of Haematology
Volume138
Issue number2
DOIs
Publication statusPublished - Jul 2007

Keywords

  • Acute myeloid leukaemia
  • Ara-C
  • Fludarabine
  • Gentuzumab ozogamicin
  • Idarubicin

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: Results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients'. Together they form a unique fingerprint.

Cite this